You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
海王生物(000078.SZ):HW130注射液获美国FDA批准进入人体临床试验
格隆汇 01-17 17:54

格隆汇1月17日丨海王生物(000078.SZ)公布,公司全资子公司深圳海王医药科技研究院有限公司(海王医药研究院)2020117日收到美国食品药品监督管理局(美国FDA”)签发的书面通知,批准海王医药研究院自主研发、具有自主知识产权的新型肿瘤血管阻断剂HW130射液在美国开展I期药物人体临床试验。

HW130注射液是海王医药研究院自主研发、具有自主知识产权的新型肿瘤血管阻断剂。经综合的临床前研究考察,HW130注射液具有显著的肿瘤血管破坏作用以及显著降低肿瘤治疗患者死亡率的作用,显著提升肿瘤综合治疗的临床效益;对正常器官组织的损伤轻微,具有高度的靶向性与安全性。该项目的开发可一定程度上解决临床未被满足的临床需求,具有较大的开发潜力与市场空间。

目前该项目已获中国、美国化合物发明专利授权。

据公司了解目前国内外无同类药物上市,同类药物多处于临床前及临床研究等不同阶段。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account